ATRA Atara Biotherapeutics, Inc.

14.40
-0.10  -1%
Previous Close 14.50
Open 14.60
Price To book 1.81
Market Cap 419.17M
Shares 29,109,000
Volume 146,142
Short Ratio 11.97
Av. Daily Volume 302,835

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial planned for 2H 2017.
ATA 129 - ALLELE
Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT)
Phase 3 trial planned for 2H 2017.
ATA 129 - MATCH
Epstein-Barr virus (EBV-PTLD) after after hematopoietic cell transplant (HCT)
Phase 1/2 trial to be initiated 2018.
ATA129 and KEYTRUDA
Nasopharyngeal carcinoma (NPC)
Phase 2 endpoint not met December 2015
PINTA 745
Protein-energy wasting
Phase 2 data released at ASH 2015. Expects to meet with FDA during 4Q 2016 to discuss further development
CMV-CTL
Refractory CMV Chorioretinitis or Meningoencephalitis

Latest News

  1. Atara Biotherapeutics to Present at Three Upcoming Investor Conferences
  2. Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
  3. Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team
  4. Atara Biotherapeutics reports 1Q loss
  5. Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights
  6. Biotech Movers: XBiotech, Atara, Bellicum
  7. Atara Bio Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with ATA129 in Nasopharyngeal Carcinoma (NPC)
  8. Atara Biotherapeutics shares rise on MS drug study results
  9. Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology (AAN) Annual Meeting 2017
  10. Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer
  11. Atara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis (MS)
  12. Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights
  13. Favorite Healthcare Stocks of Billionaire Seth Klarman’s Baupost Group
  14. Atara Biotherapeutics Inc (ATRA): Are Hedge Funds Right About This Stock?